Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$717,645.00
Feb 1, 2020
Individual or sole proprietorship
Operating Grant: COVID-19 - Vaccines
154682
The specific objectives of the Canadian 2019-nCoVrapid research funding opportunity are to:
• Contribute to the global response to the 2019-nCoV outbreak;
• Enhance local, national and/or international collaborative efforts to mitigate the rapid spread of 2019-nCoV and its potential negative consequences;
• Strengthen the understanding of the impact of 2019-nCoV on individuals and communities; and
• Provide evidence to inform clinical and public health response, and/or decision-making and planning at national and international levels.
$999,356.00
Feb 1, 2020
Individual or sole proprietorship
Operating Grant: COVID-19 - Vaccines
154681
The specific objectives of the Canadian 2019-nCoVrapid research funding opportunity are to:
• Contribute to the global response to the 2019-nCoV outbreak;
• Enhance local, national and/or international collaborative efforts to mitigate the rapid spread of 2019-nCoV and its potential negative consequences;
• Strengthen the understanding of the impact of 2019-nCoV on individuals and communities; and
• Provide evidence to inform clinical and public health response, and/or decision-making and planning at national and international levels.
$999,793.00
Feb 1, 2020
Individual or sole proprietorship
Operating Grant: COVID-19 - Vaccines
154683
The specific objectives of the Canadian 2019-nCoVrapid research funding opportunity are to:
• Contribute to the global response to the 2019-nCoV outbreak;
• Enhance local, national and/or international collaborative efforts to mitigate the rapid spread of 2019-nCoV and its potential negative consequences;
• Strengthen the understanding of the impact of 2019-nCoV on individuals and communities; and
• Provide evidence to inform clinical and public health response, and/or decision-making and planning at national and international levels.
$199,159,000.00
Nov 20, 2020
For-profit organization
Coronavirus/Pandemic Vaccine/Treatment Manufacturing Capacity
816022
This project will help develop Canada's medical countermeasures to COVID-19 and future pandemics by expanding RBI's manufacturing capabilities to create additional vaccine, therapy and fill/finish capacity at its Mississauga, Ontario site.
$49,920.00
Apr 1, 2020
For-profit organization
Feasibility study: expanding vaccination training capacity
948110
Delivering COVID vaccine to 70% of the Canadian population will be 2 to 4 times the largest vaccination project in Canada history. This will result in delays in the public getting timely access to COVID vaccinations, and avoidable physician/ER visits, hospitalizations and deaths.
$25,000.00
Apr 25, 2017
Characterization of Antigen-Adjuvant interactions by Atomic Force Microscopy
EGP
$415,000,000.00
Jul 22, 2020
For-profit organization
Sanofi FLUZONE® High-Dose Vaccine Facility and Pandemic Preparedness
815915
This project will support the development of a new bulk vaccine manufacturing facility and install state of the art drug product formulation, filling, inspection and packaging (FFIP) capabilities in an existing facility in Toronto, Ontario.
$303,341.00
Jan 21, 2021
Academia
Newcastle Disease Virus (NDV) as a novel platform for development of COVID-19 vaccines
964417
The University of Guelph developed a vaccine to protect against the novel coronavirus disease that emerged in 2019 (COVID-19) using a safe vector known as avian orthoavulavirus-1 (AOaV-1) with a transgene encoding the full-length spike protein (FLS) from severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). In a hamster challenge model of COVID-19, intranasal vaccination with AOaV-1-FLS completely protected against disease, and SARS-CoV-2 could not be detected.
$303,341.00
Jan 21, 2021
Academia
Newcastle Disease Virus (NDV) as a novel platform for development of COVID-19 vaccines
964417
The University of Guelph developed a vaccine to protect against the novel coronavirus disease that emerged in 2019 (COVID-19) using a safe vector known as avian orthoavulavirus-1 (AOaV-1) with a transgene encoding the full-length spike protein (FLS) from severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). In a hamster challenge model of COVID-19, intranasal vaccination with AOaV-1-FLS completely protected against disease, and SARS-CoV-2 could not be detected.
$10,000,000.00
Sep 1, 2022
For-profit organization
Providence COVID-19 Vaccine Development - STAGE 3
998413
Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in mid-2023 and pursue market or emergency approvals to commercialize in late 2023 or early 2024. The objective of this project is to facilitate the company's R&D efforts and vaccine development program to begin a Phase 3 clinical trial in 2023.